BRAF mutated cancers evaluated from primary tumor biopsy showed MSI high in 51.9% of samples while in BRAF mutated cancers evaluated from metastatic site biopsies showed MSI high in 11.5% of samples (Fisher’s exact test p = 0.02, Figure 1). This evidence concerns the gene BRAF and cancer.